Details for Patent: 10,420,775
✉ Email this page to a colleague
Which drugs does patent 10,420,775 protect, and when does it expire?
Patent 10,420,775 protects TAZVERIK and is included in one NDA.
This patent has one hundred and eight patent family members in thirty-six countries.
Summary for Patent: 10,420,775
| Title: | Aryl-or heteroaryl-substituted benzene compounds |
| Abstract: | The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. |
| Inventor(s): | Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano |
| Assignee: | Eisai R&D Management Co Ltd , Epizyme Inc |
| Application Number: | US15/816,907 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,420,775
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | DISCN | Yes | No | 10,420,775 | ⤷ Start Trial | METHOD OF TREATING EPITHELIOID SARCOMA | ⤷ Start Trial | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | DISCN | Yes | No | 10,420,775 | ⤷ Start Trial | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION | ⤷ Start Trial | ||||
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | DISCN | Yes | No | 10,420,775 | ⤷ Start Trial | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,420,775
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 086008 | ⤷ Start Trial | |||
| Australia | 2012242595 | ⤷ Start Trial | |||
| Brazil | 112013026324 | ⤷ Start Trial | |||
| Brazil | 122020006541 | ⤷ Start Trial | |||
| Canada | 2832843 | ⤷ Start Trial | |||
| Canada | 3086473 | ⤷ Start Trial | |||
| Chile | 2013002898 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
